IDYA News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$3.17B

Volume

475.27K

Next Earnings

November 3rd

Mkt Cap

$3.17B

Volume

475.27K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsIDEAYA Biosciences announced positive Phase 2/3 trial results for darovasertib combined with crizotinib in treating metastatic uveal melanoma. The combination showed a median progression-free survival of 6.9 months versus 3.1 months for standard therapy, with a 37.1% overall response rate compared to 5.8%. The company plans to submit an FDA New Drug Application in the second half of 2026. IDYA shares surged 26.36% in premarket trading.Benzinga · Apr 13, 2026

Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing TechnologiesThe global antibody optimization service market is projected to grow from USD 2.77 billion in 2024 to USD 6.07 billion by 2034, driven by advances in gene-editing technologies, AI/computational tools, and increasing biologics R&D.GlobeNewswire Inc. · Dec 17, 2025

Melanoma Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsightOver 150 pharmaceutical companies are actively developing 170+ pipeline melanoma drugs, with promising therapies in various clinical trial stages targeting improved treatment outcomes through immunotherapies and targeted treatments.GlobeNewswire Inc. · Oct 14, 2025

IDEAYA (IDYA) Q2 Net Loss Improves 27%IDEAYA Biosciences reported a Q2 2025 net loss of $0.88 per share with no revenue, but maintained strong cash reserves of $991.9 million. The company continues advancing its cancer therapy pipeline, with key clinical trials progressing in darovasertib and other oncology programs.The Motley Fool · Aug 5, 2025

Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsightThe melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.GlobeNewswire Inc. · Jul 22, 2025

Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - BenzingaKura Sushi USA reported weak Q3 results, missing analyst estimates. Several other companies, including LegalZoom.com, Stardust Power, 10x Genomics, IDEAYA Biosciences, and uniQure, also saw their shares decline in pre-market trading.Benzinga · Jul 10, 2024

Company News for July 9, 2024 - July 9, 2024 - Zacks Investment ResearchMorphic Holding surged 75.1% on news of Eli Lilly's $3.2 billion acquisition. Ideaya Biosciences gained 15.3% after positive phase 2 trial results. Etsy fell 5.3% due to product sale restrictions. Intel jumped 6.2% following positive remarks from Melius Research.Zacks Investment Research · Jul 9, 2024

BTIG lifts Ideaya Biosciences target to $62 on study data - Investing.comBTIG increased its price target on Ideaya Biosciences to $62 from $55, citing positive data from a Phase 2 study of the company's drug IDE397 as a monotherapy for treating certain cancers.Investing.com · Jul 8, 2024

Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Paramount ... - BenzingaParamount Global shares jumped 7.5% in pre-market trading after the company announced a $28 billion merger deal with Skydance Media to create a new entity called 'New Paramount'. Several other stocks also saw significant pre-market movements.Benzinga · Jul 8, 2024

Unveiling 5 Analyst Insights On IDEAYA BiosciencesIn the preceding three months, 5 analysts have released ratings for IDEAYA Biosciences (NASDAQ:IDYA), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 2 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $55.4, a high estimate of $60.00, and a low estimate of $52.00. This current average has increased by 24.02% from the previous average price target of $44.67. Understanding Analyst Ratings: A Comprehensive Breakdown The analysis of recent analyst actions sheds light on the perception of IDEAYA Biosciences by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Robert Driscoll Wedbush Maintains Outperform $52.00 - Yigal Nochomovitz Citigroup Raises Buy $60.00 $40.00 Justin Zelin BTIG Announces Buy $55.00 - Anupam Rama JP Morgan Raises Overweight $57.00 $51.00 Gregory Renza RBC Capital Raises Outperform $53.00 $43.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to IDEAYA Biosciences. This information provides ...Full story available on Benzinga.comBenzinga · May 8, 2024

IDYAIDEAYA Biosciences, Inc. Common Stock

IDYA

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any IDYA yet.

Related Tickers

Earnings

Mkt Cap

$3.17B

Volume

475.27K

Next Earnings

November 3rd